

May 13, 2016

Financial Summary
(For the fiscal year ended March 31, 2016)
[Under Japanese GAAP]
(Consolidated)

Listed Company: Zeria Pharmaceutical Co., Ltd.

(Stock Exchange: First Section of Tokyo Stock Exchange)

Code Number: 4559

(URL: <http://www.zeria.co.jp/>)

Representative: Mitsuhiro Ibe, Representative Director, President & COO

Person in charge of reference: Shinya Sugawara, Director, Public Relations Division

TEL (03) 3661-1039

Scheduled date to ordinary general meeting of shareholders: June 29, 2016

Scheduled date to commencement of dividend payments: June 30, 2016

Scheduled date to submit the Securities Report: June 29, 2016

Preparation of supplementary documents to the financial results: Yes

Holding of financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2015 through March 31, 2016)

(1) Consolidated Financial Results

(Percentage figures indicate change from the previous year.)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent	
Year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
March 31, 2016	62,475	2.4	4,565	70.4	4,450	60.7	3,513	37.4
March 31, 2015	61,012	(1.6)	2,678	(60.6)	2,770	(59.3)	2,557	(51.5)

Note: Comprehensive income: For the year ended March 31, 2016: 4,030 million yen [(13.7)%]

For the year ended March 31, 2015: 4,669 million yen [(46.3)%]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ordinary income to total assets	Operating income to net sales
Year ended	Yen	Yen	%	%	%
March 31, 2016	66.15	—	5.6	4.1	7.3
March 31, 2015	48.15	—	4.2	2.8	4.4

Reference: Equity in income of affiliates accounted for by the equity method: For the year ended March 31, 2016: — million yen

For the year ended March 31, 2015: — million yen

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
March 31, 2016	119,178	64,067	53.5	1,199.94
March 31, 2015	96,268	62,570	65.0	1,178.00

Reference: Equity: As of March 31, 2016: 63,734 million yen As of March 31, 2015: 62,570 million yen

(3) Consolidated Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at the end of term
Year ended	Million yen	Million yen	Million yen	Million yen
March 31, 2016	5,694	(32,709)	22,416	12,210
March 31, 2015	653	475	(5,839)	17,880

2. Dividends

	Annual dividends					Total dividends paid (Total)	Payout ratio (Consolidated)	Dividend rate for net assets (Consolidated)
	First quarter	Second quarter	Third quarter	Year-end	Total			
Year ended	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
March 31, 2015	—	15.00	—	15.00	30.00	1,593	62.3	2.6
March 31, 2016	—	15.00	—	16.00	31.00	1,646	46.9	2.6
Year ending March 31, 2017 (Forecast)	—	16.00	—	16.00	32.00		47.2	

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2017 (April 1, 2016 through March 31, 2017)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First six months	32,000	5.5	2,200	4.0	2,000	26.2	1,800	11.3	33.89
Full year	66,000	5.6	4,800	5.1	4,600	3.4	3,600	2.5	67.78

* Notes

(1) Significant changes of subsidiaries during the fiscal year ended March 31, 2016 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: — (Company name: —) Exclusion: — (Company name: —)

(2) Changes in the accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

2) Changes in accounting policies due to other reasons: None

3) Changes in accounting estimates: None

4) Restatement of prior period financial statements after error corrections: None

(3) Number of shares issued (common stock)

1) Number of shares issued as of the end of the term (including treasury stock):

As of March 31, 2016: 53,119,190 shares As of March 31, 2015: 53,119,190 shares

2) Number of shares of treasury stock as of the end of the term:

As of March 31, 2016: 3,871 shares As of March 31, 2015: 3,355 shares

3) Average number of shares during the term:

For the year ended March 31, 2016: 53,115,619 shares

For the year ended March 31, 2015: 53,116,149 shares

Reference: Summary of Non-consolidated Financial Results

Non-consolidated Financial Highlights (April 1, 2015 through March 31, 2016)

(1) Non-consolidated Financial Results

(Percentage figures indicate change from the previous year.)

	Net sales		Operating income		Ordinary income		Profit	
Year ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
March 31, 2016	48,269	(1.2)	1,388	136.3	2,589	49.4	2,599	13.4
March 31, 2015	48,872	(6.2)	587	(86.6)	1,733	(67.0)	2,292	(46.0)

	Basic earnings per share	Diluted earnings per share
Year ended	Yen	Yen
March 31, 2016	48.93	—
March 31, 2015	43.16	—

(2) Non-consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
March 31, 2016	100,404	53,510	53.3	1,007.44
March 31, 2015	79,608	53,100	66.7	999.71

Reference: Equity: As of March 31, 2016: 53,510 million yen As of March 31, 2015: 53,100 million yen

* Indication about Carrying-Out of the Audit Procedures

This Financial Summary is not subject to the audit procedures based on the Financial Instruments and Exchange Act of Japan. At the time of disclosure of this financial report, the audit procedures for consolidated financial statements based on the Financial Instruments and Exchange Act have not been completed.

* Cautionary Statement of Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.